Stock Ideas
New
Stocks
Funds
Screener
Sectors
Watchlists
XNCR

XNCR - Xencor Inc Stock Price, Fair Value and News

20.61USD-0.70 (-3.28%)Market Closed

Market Summary

XNCR
USD20.61-0.70
Market Closed
-3.28%

XNCR Alerts

  • Big fall in Revenue (Y/Y)
  • Losses in recent quarter

XNCR Stock Price

View Fullscreen

XNCR RSI Chart

XNCR Valuation

Market Cap

1.3B

Price/Earnings (Trailing)

-9.59

Price/Sales (Trailing)

7.84

EV/EBITDA

-27.01

Price/Free Cashflow

24.13

XNCR Price/Sales (Trailing)

XNCR Profitability

EBT Margin

-50.47%

Return on Equity

-21.63%

Return on Assets

-14.98%

Free Cashflow Yield

4.14%

XNCR Fundamentals

XNCR Revenue

Revenue (TTM)

162.2M

Rev. Growth (Yr)

-32.47%

Rev. Growth (Qtr)

-71.35%

XNCR Earnings

Earnings (TTM)

-132.5M

Earnings Growth (Yr)

-11.96%

Earnings Growth (Qtr)

-240.45%

Breaking Down XNCR Revenue

Last 7 days

-2.7%

Last 30 days

4.7%

Last 90 days

-7.7%

Trailing 12 Months

-19.7%

How does XNCR drawdown profile look like?

XNCR Financial Health

Current Ratio

7.08

Debt/Equity

0.02

Debt/Cashflow

4.84

XNCR Investor Care

Shares Dilution (1Y)

2.11%

Diluted EPS (TTM)

-2.18

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
2024162.2M000
202398.0M113.4M145.3M168.3M
2022326.6M289.4M297.0M164.6M
2021124.3M178.7M163.0M275.1M
202077.1M70.7M84.3M122.7M
2019182.7M172.0M164.7M156.7M
20180078.8M77.8M
201783.8M30.3M29.5M53.2M
201633.5M98.5M102.8M87.5M
20158.8M9.0M11.7M27.8M
201411.0M7.9M5.6M9.5M
20139.7M9.8M10.0M10.2M
20120009.5M
GRUFITY'S FAIR VALUE MODEL

Stocks Marked 'Very Cheap' by Grufity's Fair Value Model Have Outperformed Russell 2000 Index

Small Caps and Mid Caps are mostly overlooked by investors as all the focus goes to Magnificent 7. These stocks that are not part of the beauty contest require a deeper look. However, all large cap stocks were once small caps. Grufity's Fair Value model opens up this unverse as it separates high-performing, rewarding stocks from low-performing risky stocks. <b>Russell 2000 stocks that were marked 'Very Cheap' by the model doubled in three years while the index was flat.</b>

PurpleZone


Returns of $10,000 invested in:

Very Cheap Stocks: $21,859
Russell 2000 Index: $10,334
Very Expensive Stocks: $8,224


Russell 2000 stocks considered 'Very Cheap' by the model greatly outperformed Russell 2000 index and the 'Very Expensive' bucket over past three years.

Russell 2000 Index
Very Expensive Stocks
Very Cheap Stocks
Try For Just $1.99

Tracking the Latest Insider Buys and Sells of Xencor Inc

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
May 02, 2024
valente nancy
sold
-111,872
23.5768
-4,745
evp, chief development officer
Apr 09, 2024
cornelissen bart jan
acquired
-
-
42,265
sr. vice president & cfo
Mar 11, 2024
eckert celia
sold
-19,976
23.5018
-850
svp, general counsel
Mar 11, 2024
desjarlais john r
sold
-30,082
23.5018
-1,280
sr. vice president & cso
Mar 11, 2024
dahiyat bassil i
sold
-64,418
23.5018
-2,741
president & ceo
Mar 11, 2024
kuch john j
sold
-19,953
23.5018
-849
sr. vice president & cfo
Mar 06, 2024
gustafson kurt a
acquired
160,950
10.73
15,000
-
Mar 06, 2024
gustafson kurt a
sold
-324,453
23.1752
-14,000
-
Mar 05, 2024
valente nancy
acquired
-
-
19,634
evp, chief development officer
Mar 05, 2024
eckert celia
acquired
-
-
13,089
svp, general counsel

1–10 of 50

Which funds bought or sold XNCR recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
Jun 11, 2024
EverSource Wealth Advisors, LLC
sold off
-100
-2,187
-
-%
Jun 04, 2024
DekaBank Deutsche Girozentrale
unchanged
-
34,000
701,000
-%
May 28, 2024
TEACHERS RETIREMENT SYSTEM OF THE STATE OF KENTUCKY
unchanged
-
18,000
428,000
-%
May 21, 2024
China Universal Asset Management Co., Ltd.
added
66.95
111,138
260,138
0.03%
May 16, 2024
COMERICA BANK
reduced
-11.09
-38,340
485,510
-%
May 16, 2024
JANE STREET GROUP, LLC
reduced
-63.95
-555,262
334,318
-%
May 16, 2024
CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM
reduced
-5.14
-13,759
1,219,410
-%
May 15, 2024
DCF Advisers, LLC
reduced
-11.86
-409,077
4,624,700
2.28%
May 15, 2024
Royal Bank of Canada
reduced
-89.28
-346,000
44,000
-%
May 15, 2024
SEGALL BRYANT & HAMILL, LLC
sold off
-100
-3,286,910
-
-%

1–10 of 48

Are Funds Buying or Selling XNCR?

Are funds buying XNCR calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own XNCR
No. of Funds

Unveiling Xencor Inc's Major ShareHolders

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Feb 16, 2024
t. rowe price investment management, inc.
2.2%
1,351,367
SC 13G/A
Feb 14, 2024
t. rowe price investment management, inc.
2.2%
1,351,367
SC 13G
Feb 14, 2024
ecor1 capital, llc
8.7%
5,282,516
SC 13G/A
Feb 14, 2024
price t rowe associates inc /md/
5.7%
3,489,902
SC 13G/A
Feb 13, 2024
vanguard group inc
11.12%
6,767,249
SC 13G/A
Feb 12, 2024
primecap management co/ca/
14.62%
8,901,607
SC 13G/A
Feb 09, 2024
fmr llc
-
0
SC 13G/A
Jan 25, 2024
state street corp
5.47%
3,326,856
SC 13G/A
Jan 19, 2024
blackrock inc.
18.6%
11,322,242
SC 13G/A
Feb 14, 2023
price t rowe associates inc /md/
5.4%
3,218,761
SC 13G/A

Recent SEC filings of Xencor Inc

View All Filings
Date Filed Form Type Document
Jun 13, 2024
8-K
Current Report
May 09, 2024
10-Q
Quarterly Report
May 09, 2024
8-K
Current Report
May 03, 2024
4
Insider Trading
May 02, 2024
144
Notice of Insider Sale Intent
Apr 24, 2024
ARS
ARS
Apr 24, 2024
DEF 14A
DEF 14A
Apr 24, 2024
DEFA14A
DEFA14A
Apr 11, 2024
3
Insider Trading
Apr 11, 2024
4
Insider Trading

Peers (Alternatives to Xencor Inc)

NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
53.7B
6.8B
13.11% 15.14%
-8.99
7.84
-64.45% -224.75%
22.5B
216.3K
-0.77% 465779.94%
-2.5K
104.0K
- -8.13%
20.3B
2.0B
8.19% -19.39%
-61.09
10.13
75.20% 68.82%
15.9B
2.5B
5.74% -10.79%
77.15
6.41
13.74% 186.89%
13.9B
3.8B
9.90% 2.05%
18.71
3.7
8.58% 129.81%
MID-CAP
5.2B
107.9M
0.17% 71.70%
-9.53
48.09
54.84% -28.31%
5.2B
524.1M
3.28% -53.81%
-12.38
9.86
394.93% 39.61%
3.5B
251.0M
-6.27% -10.41%
-11.81
13.95
73.58% -86.73%
3.2B
240.7M
15.67% -25.01%
-6.79
12.77
-1.03% -213.92%
2.5B
813.8M
1.62% -37.45%
-1.4K
3.03
56.43% 98.83%
2.0B
996.6M
11.65% 94.95%
-5.07
2.03
-26.66% 65.49%
SMALL-CAP
1.8B
411.3M
-7.16% 29.42%
27.32
4.32
60.38% -34.49%
534.3M
881.7K
22.84% 567.64%
-15.83
481.06
-77.61% 33.36%
235.5M
4.2M
-17.34% 57.33%
-1.89
56.62
-66.30% 48.24%
22.1M
2.1M
36.17% 271.01%
-0.95
7.61
-13.45% 69.54%

Xencor Inc News

Latest updates
Seeking Alpha30 hours ago
Defense World12 Jun 202411:22 am
Yahoo Movies UK11 Jun 202404:08 am
MarketBeat10 Jun 202403:53 pm

Xencor Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)
Income Statement (Quarterly)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q1
Revenue-71.3%12,805,00044,689,00059,164,00045,523,00018,962,00021,609,50027,300,00030,175,00085,495,000153,998,00019,683,00067,447,00034,000,00041,854,00035,366,00013,089,00032,385,0003,508,00021,760,00019,485,000111,939,000
Operating Expenses-10.6%70,660,00079,008,50077,432,00071,520,00079,706,00064,202,00065,647,00058,175,00059,029,00062,363,50060,983,00058,360,00049,637,00055,552,00052,088,00050,689,00041,162,00034,088,50036,036,00039,057,00033,695,000
  S&GA Expenses-10.3%13,787,00015,375,00012,493,00011,460,00014,154,00012,751,00012,374,00011,091,00011,273,00011,375,00010,373,0008,863,0008,226,0007,603,0007,636,0007,231,0007,219,0006,749,5006,266,0005,758,0005,512,000
  R&D Expenses-10.6%56,873,00063,633,50064,939,00060,060,00065,552,00051,451,00053,273,00047,084,00047,756,00050,988,50050,610,00049,497,00041,411,00047,949,00044,452,00043,458,00033,943,00027,339,00029,770,00033,299,00028,183,000
EBITDA Margin7.0%-0.29-0.310.200.070.050.010.000.060.050.05-0.57-0.34---------
Interest Expenses7.4%7,471,0006,954,0005,016,0003,764,0002,892,0002,068,0001,379,000717,000653,000291,000196,000147,000215,000712,0001,423,0002,090,0003,039,0003,418,5003,699,0003,615,0002,886,000
Income Taxes-100.0%-5,811,000----415,0001,100,000-----------288,000-350,00050,000900,000
Earnings Before Taxes100.0%--13,453,000-24,269,000---12,457,000-31,671,000--73,061,000-40,191,000---13,691,000-12,550,000-35,018,000-8,074,000-27,200,000-10,574,000-15,984,00080,945,000
EBT Margin-3.8%-0.50-0.490.03-0.10-0.11-0.07-0.040.020.020.02-0.62-0.39---------
Net Income-240.4%-68,033,000-19,983,500-24,269,000-20,189,000-60,763,000-8,324,500-32,759,000-35,798,00017,983,00073,105,500-40,191,00052,136,000-2,464,000-13,691,000-12,550,000-34,591,000-8,179,000-26,912,000-10,224,000-16,034,00080,045,000
Net Income Margin-9.8%-0.82-0.74-0.76-1.05-1.37-0.360.080.050.320.30-0.030.13---------
Free Cashflow-130.7%-55,390,000180,226,000-30,113,000-42,053,000-41,397,000-34,397,000-15,253,00031,915,0003,726,00055,470,000-41,768,000-11,937,000---------
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q1
Assets-7.2%884953778778803846835851858838697696693703646645667670686685697
  Current Assets-9.8%562623571594630675668586506424330481591638571603588558574527489
    Cash Equivalents-42.3%31.0054.0053.0035.0072.0054.0053.0049.0078.0014341.0011617716458.0011074.0050.0051.0033.0022.00
  Net PPE-3.9%64.0066.0068.0068.0067.0059.0051.0039.0028.0028.0024.0023.0022.0022.0020.0016.0017.0016.0014.0012.0011.00
Liabilities-4.1%27228410999.0012011911310995.0010578.0049.0010913178.0074.0074.0077.0076.0077.0087.00
  Current Liabilities-6.3%79.0085.0053.0045.0065.0064.0090.0075.0061.0071.0044.0046.0010012170.0066.0066.0067.0064.0064.0073.00
  Long Term Debt-14.7%12.0015.00-------------------
    LT Debt, Non Current-14.7%12.0015.00-------------------
Shareholder's Equity-8.4%613669669679684727723742763734619647584572568571593593610608610
  Retained Earnings-14.7%-532-464-445-421-399-338-326-293-259-283-356-315-368-365-352-339-304-296-269-259-243
  Additional Paid-In Capital1.2%1,1441,1311,1141,1011,0861,0721,0581,0441,0291,018975962951938919908896888878865852
Shares Outstanding1.0%62.0061.0061.0061.0060.0060.0060.0060.0059.0058.0058.0058.00---------
Minority Interest-200.6%-0.340.00-------------------
Float----1,502---1,624---2,000---1,844---2,292-
Cashflow (Last 12 Months)
(In Thousands)
Cashflow (Quarterly)
(In Thousands)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q1
Cashflow From Operations-130.5%-55,258181,206-27,281-38,200-30,614-24,431-1,16844,2695,81561,790-39,023-9,654-29,96617,084-3,866-27,6829,460-19,577-6,477109,156-18,728
  Share Based Compensation-22.3%11,42114,69712,89613,56312,59912,74512,76012,60310,80510,3898,9439,3508,2938,5588,3188,2316,5127,1789,5149,3035,856
Cashflow From Investing115.9%32,318-203,13045,326-1,40548,14424,5483,125-75,639-71,7597,860-38,848-53,30938,04878,779-50,56059,40812,56515,72722,060-102,43013,673
Cashflow From Financing-99.2%18622,9833561,9219221,1711,2872,51373132,6303,2291,8405,3399,5872,9864,0001,4712,9733,0493,973667
Get Full Access to Grufity – and Unlimited Downloads
Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.
Try For Just $1.99

XNCR Income Statement

2024-03-31
Consolidated Statements of Comprehensive Loss - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Statement of Comprehensive Income [Abstract]  
Net loss$ (68,709)$ (60,763)
Net unrealized gain (loss) on marketable debt securities(1,445)3,327
Comprehensive loss(70,154)(57,436)
Comprehensive loss attributable to non-controlling interest(676)0
Net loss attributable to Xencor, Inc.$ (69,478)$ (57,436)

XNCR Balance Sheet

2024-03-31
Consolidated Balance Sheets - USD ($)
$ in Thousands
Mar. 31, 2024
Dec. 31, 2023
Current assets  
Cash and cash equivalents$ 31,034$ 53,790
Marketable debt securities460,367497,725
Marketable equity securities44,53542,210
Accounts receivable9,58011,290
Prepaid expenses and other current assets16,73618,145
Total current assets562,252623,160
Property and equipment, net63,54066,124
Patents, licenses, and other intangible assets, net18,85218,663
Restricted cash382380
Marketable debt securities - long term154,960145,512
Marketable equity securities - long term43,56064,210
Right of use (ROU) asset40,21133,995
Other assets498648
Total assets884,255952,692
Current liabilities  
Accounts payable16,01113,914
Accrued expenses13,49123,564
Income tax payable5,7825,782
Lease liabilities2,0793,435
Deferred income34,08831,682
Debt7,9516,332
Total current liabilities79,40284,709
Lease liabilities, net of current portion66,81059,025
Deferred income, net of current portion113,367125,183
Debt, net of current portion12,48914,642
Total liabilities272,068283,559
Commitments and contingencies
Stockholders’ equity  
Preferred stock, $0.01 par value: 10,000,000 authorized shares; -0- issued and outstanding shares at March 31, 2024 and December 31, 202300
Common stock, $0.01 par value: 200,000,000 authorized shares at March 31, 2024 and December 31, 2023; 61,634,685 issued and outstanding at March 31, 2024 and 60,998,191 issued and outstanding at December 31, 2023617611
Additional paid-in capital1,144,4681,131,266
Accumulated other comprehensive (loss) income(154)1,291
Accumulated deficit(532,405)(464,372)
Total stockholders’ equity attributable to Xencor, Inc.612,526668,796
Non-controlling interest(339)337
Total stockholders’ equity612,187669,133
Total liabilities and stockholders’ equity$ 884,255$ 952,692
XNCR
Xencor, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma. It develops Plamotamab, a bispecific antibody, which is in Phase I clinical trial to treat non-Hodgkin lymphoma; Vudalimab, a bispecific antibody, which is in Phase II clinical trial to treat metastatic castration-resistant prostate cancer and other solid tumor types. The company is also developing XmAb306, which is in Phase I clinical trial to treat solid tumors; XmAb104, which is in Phase I clinical trial to treat patients with selected solid tumors; XmAb564 that is in Phase Ib clinical trial to treat autoimmune diseases; AMG 509, which is in Phase I clinical trial to treat prostate cancer; XmAb819 for patients with renal cell carcinoma; Novartis XmAb, which is in Phase I clinical trial; XmAb541 for the treatment of ovarian cancer; and XmAb662 which is in Phase I clinical trial to treat patients with solid tumors. It develops VIR-3434, which is in Phase II clinical trial for patients with hepatitis B virus infection; and VIR-2482 that is in Phase 1/2 clinical trial to trat influenza A. The company develops AIMab7195 to reduce blood serum levels of IgE that mediates allergic responses and allergic disease; Obexelimab to treat autoimmune disease; and Xpro1595 to treat patients with Alzheimer's disease, mild cognitive impairment, and depression. It has a license agreement with Caris Life Sciences. Xencor, Inc. was incorporated in 1997 and is headquartered in Monrovia, California.
 CEO
 WEBSITExencor.com
 INDUSTRYBiotechnology
 EMPLOYEES281

Xencor Inc Frequently Asked Questions


What is the ticker symbol for Xencor Inc? What does XNCR stand for in stocks?

XNCR is the stock ticker symbol of Xencor Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Xencor Inc (XNCR)?

As of Thu Jun 13 2024, market cap of Xencor Inc is 1.31 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of XNCR stock?

You can check XNCR's fair value in chart for subscribers.

What is the fair value of XNCR stock?

You can check XNCR's fair value in chart for subscribers. The fair value of Xencor Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Xencor Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for XNCR so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Xencor Inc a good stock to buy?

The fair value guage provides a quick view whether XNCR is over valued or under valued. Whether Xencor Inc is cheap or expensive depends on the assumptions which impact Xencor Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for XNCR.

What is Xencor Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Thu Jun 13 2024, XNCR's PE ratio (Price to Earnings) is -9.92 and Price to Sales (PS) ratio is 8.1. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. XNCR PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Xencor Inc's stock?

In the past 10 years, Xencor Inc has provided 0.067 (multiply by 100 for percentage) rate of return.